计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 4 篇同行评审文献引用。
T0070907 具有抗微管、 抗肿瘤和放射增敏属性。它降低微管蛋白水平,这与细胞周期阻滞、细胞凋亡有关,也可减少大肠癌细胞的转移。T0070907 用作乳腺癌的治疗靶点。刺激蛋白酶体依赖的微管蛋白降解。
T0070907 已被用于减少过氧化物酶体增殖物激活受体 γ(PPAR-γ)在脂多糖 (LPS) 诱导的白血病 RAW264.7 细胞株中的表达。它也被用于评价汉黄芩素在减轻乙醇诱导的 RAW264.7 细胞系炎症中的作用。
T0070907 或苯甲酰胺已在大鼠海马脑片中用作 ADP-核糖基转移酶 (ADPRT) 抑制剂 。也有用于诊断为急性单纯性尿路感染患者的尿液分析 。
Information
T0070907 is a potent and selectivePPARγinhibitor withIC50of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. T0070907 significantly decreases the levels ofDNA-PKcsandRAD51proteins in ME-180 and SiHa cells.
In vitro
T0070907 is a potent and selective PPARγ antagonist. With an apparent binding affinity (concentration at 50% inhibition of [3H] rosiglitazone binding or IC50) of 1 nM, T0070907 covalently modifies PPARγ on cysteine 313 in helix 3 of human PPARγ2. T0070907 blocks PPARγ function in both cell-based reporter gene and adipocyte differentiation assays. Consistent with its role as an antagonist of PPARγ, T0070907 blocks agonist-induced recruitment of coactivator-derived peptides to PPARγ in a homogeneous time-resolved fluorescence-based assay and promotes recruitment of the transcriptional corepressor NCoR to PPARγ in both glutathione S-transferase pull-down assays and a PPARγ/retinoid X receptor (RXR) α-dependent gel shift assay. Studies with mutant receptors suggest that T0070907 modulates the interaction of PPARγ with these cofactor proteins by affecting the conformation of helix 12 of the PPARγ ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARγ/RXRα heterodimer can be almost completely reversed by the simultaneous treatment with RXRα agonist LGD1069, T0070907 treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARγ/RXRα heterodimer. T0070907 treatment inhibits proliferation, invasion and migration but does not significantly affect apoptosis. Molecular inhibition using a dominant negative (Δ462) receptor yields similar results. T007 also mediates a dose-dependent decrease in phosphorylation of PPARγ, and its ability to bind to DNA, and may directly affect mitogen-activated protein kinase signaling.
In vivo
Lipopolysaccharide preconditioning significantly attenuates the development of renal dysfunction, hepatocellular injury, and circulatory failure as well as the increase in the plasma levels of interleukin-1 [beta] caused by severe endotoxemia. T0070907 can attenuate all of these beneficial effects afforded by preconditioning with lipopolysaccharide
Cell Data
cell lines:LNCaP and LAPC4
Concentrations:20 μM and higher concentrations
Incubation Time:48 h
Powder Purity:≥99%
H319: 引起严重眼睛刺激
H302: 吞食有害
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P501: 将内容物/容器处理到。。。
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P330: 漱口
P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。
P301+P317: 如果被吞咽:请寻求医疗帮助。
P337+P317: 如果眼睛刺激持续:寻求医疗帮助。
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | T408157 |